StreetInsider.com News Articles

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Thu, 22 Oct 2026 08:53:00 -0400

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

Discussion features Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer

Access the segment here

CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the release of

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Thu, 22 Oct 2026 08:53:00 -0400

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

Access the segment here

Form 8-K Ernexa Therapeutics Inc. For: Oct 15

Thu, 15 Oct 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20261015/27194244.html

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Mon, 12 Oct 2026 16:05:00 -0400

Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET

Register here

CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, member of Ernexa’s Scientific

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Mon, 12 Oct 2026 16:05:00 -0400

Register here

Ernexa presents ERNA-101 ovarian cancer data at MD Anderson event

Tue, 06 Oct 2026 08:58:31 -0400

Ernexa Therapeutics (NASDAQ: ERNA) announced that preclinical data from its lead oncology program, ERNA-101, were selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center in Houston.

The presentation took place October 6, 2026, on MD Anderson's campus. The session, titled "IL7-IL15-iMSCs (ERNA-101): Allogeneic, Off-the-Shelf, Next-Generation Immune-Enhancing Cell Therapy of Cancer," featured preclinical findings from models of high-grade serous ovarian cancer.

According to the company's press release, ERNA-101 promoted immune cell recruitment, including T cells and proinflammatory macrophages, and was associated with tumor regression and improved survival

Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center

Tue, 06 Oct 2026 08:55:00 -0400

Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston

CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer

Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center

Tue, 06 Oct 2026 08:55:00 -0400

Ernexa appoints oncology veteran Spiegel to board ahead of clinic

Thu, 01 Oct 2026 09:20:32 -0400

Ernexa Therapeutics (NASDAQ: ERNA) has appointed Robert J. Spiegel, M.D., FACP, to its board of directors as the Cambridge, Mass.-based cell therapy company prepares to advance its lead program, ERNA-101, into clinical development.

Dr. Spiegel brings more than 25 years of experience at Schering-Plough Research Institute, where he served as Chief Medical Officer, along with expertise spanning oncology, clinical development and regulatory strategy.

"His experience aligns directly with where we are headed as we move ERNA-101 toward the clinic," said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics.

ERNA-101 is initially being developed for platinum-resistant ovarian cancer. The therapy uses induced

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

Thu, 01 Oct 2026 09:20:00 -0400

CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1

Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors

Access the Ernexa CEO Corner here

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today released a new installment of its CEO Corner series featuring President

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

Thu, 01 Oct 2026 09:20:00 -0400

Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors

Access the Ernexa CEO Corner here

Ernexa reports positive safety data for ERNA-101 cell therapy

Wed, 30 Sep 2026 08:33:56 -0400

Ernexa Therapeutics (Nasdaq: ERNA) reported results from three preclinical safety studies of its lead cell therapy candidate, ERNA-101, as the company prepares for a planned Investigational New Drug (IND) submission in the fourth quarter of 2026.

According to a company statement, a 50-day repeat-dose GLP toxicology study in tumor-bearing mice with intact immune systems showed no ERNA-101-related adverse findings at any dose level tested, including no clinical pathology or histopathology findings. A single-dose assessment also showed no evidence of acute cytokine release.

In tumorigenicity studies, no teratoma formation was observed in ERNA-101-treated animals through the six-month in-life phase. Histopathologic evaluation of the

Ernexa reports positive safety data for ERNA-101 cell therapy

Wed, 30 Sep 2026 08:33:56 -0400

In tumorigenicity studies, no teratoma formation was observed in ERNA-101-treated animals through the six-month in-life phase. Histopathologic evaluation of the

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

Wed, 30 Sep 2026 08:32:00 -0400

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release

No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy

Biodistribution study showed no significant ERNA-101 signal in tumor-free animals or non-tumor tissues, supporting ERNA-101’s tumor-homing delivery strategy

Encouraging safety results build on previously reported complete tumor clearance and durable survival in ovarian cancer models, strengthening the nonclinical foundation for

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

Wed, 30 Sep 2026 08:32:00 -0400

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release

No teratoma formation observed in ERNA-101-treated animals through the six-month tumorigenicity in-life phase, addressing a fundamental safety consideration for an iPSC-derived cell therapy

Biodistribution study showed no significant ERNA-101 signal in tumor-free animals or non-tumor tissues, supporting ERNA-101’s tumor-homing delivery strategy

Encouraging safety results build on previously reported complete tumor clearance and durable survival in ovarian cancer models, strengthening the nonclinical foundation for

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

Tue, 29 Sep 2026 09:15:00 -0400

Ernexa selected for the Emerging Track, recognizing the Company among emerging
innovators in the cell and gene therapy sector

President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on
October 6, 2026, at 1:30 PM

Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101
in platinum-resistant ovarian cancer and its potential for broader expansion across
ovarian cancer and other solid tumor indications

Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf
treatment solution without the need for patient-specific cell harvesting

ERNA-101 remains on track for planned IND submission

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

Tue, 29 Sep 2026 09:15:00 -0400

Ernexa selected for the Emerging Track, recognizing the Company among emerging
innovators in the cell and gene therapy sector

President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on
October 6, 2026, at 1:30 PM

Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101
in platinum-resistant ovarian cancer and its potential for broader expansion across
ovarian cancer and other solid tumor indications

Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf
treatment solution without the need for patient-specific cell harvesting

ERNA-101 remains on track for planned IND submission

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

Tue, 29 Sep 2026 09:15:00 -0400

Ernexa selected for the Emerging Track, recognizing the Company among emerging
innovators in the cell and gene therapy sector

President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on
October 6, 2026, at 1:30 PM

Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101
in platinum-resistant ovarian cancer and its potential for broader expansion across
ovarian cancer and other solid tumor indications

Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf
treatment solution without the need for patient-specific cell harvesting

ERNA-101 remains

Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy

Tue, 29 Sep 2026 09:15:00 -0400

Ernexa selected for the Emerging Track, recognizing the Company among emerging
innovators in the cell and gene therapy sector

President & CEO Sanjeev Luther to deliver an Innovation Spotlight presentation on
October 6, 2026, at 1:30 PM

Presentation to highlight Ernexa’s focused oncology strategy, beginning with ERNA-101
in platinum-resistant ovarian cancer and its potential for broader expansion across
ovarian cancer and other solid tumor indications

Differentiated synthetic iMSC platform designed to provide a scalable, off-the-shelf
treatment solution without the need for patient-specific cell harvesting

ERNA-101 remains

Form 3 Ernexa Therapeutics Inc. For: Sep 14 Filed by: Spiegel Robert J.

Tue, 22 Sep 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20260922/27091192.html

Ernexa Therapeutics adds former Schering-Plough CMO to board

Thu, 17 Sep 2026 08:42:15 -0400

Ernexa Therapeutics (NASDAQ: ERNA), a Cambridge, Mass.-based cell therapy developer, has appointed Robert J. Spiegel, M.D., FACP, to its board of directors, according to a company statement.

Dr. Spiegel spent more than 25 years at Schering-Plough Research Institute, serving as its Chief Medical Officer from 1998 to 2009. He later held the same role at PTC Therapeutics from 2014 to 2016. He is currently founder and principal of Spiegel Consulting LLC and an associate professor of medicine at Weill Cornell Medical College.

During his time at Schering-Plough, Dr. Spiegel was involved in the development and regulatory approval of multiple therapies, including alpha-interferon

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Thu, 17 Sep 2026 08:42:00 -0400

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics

Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the appointment of Robert J. Spiegel, M.D., FACP, to its Board of Directors.

Dr. Spiegel is an accomplished physician, biopharmaceutical executive and drug developer

Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors

Thu, 17 Sep 2026 08:42:00 -0400

Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics

Appointment further strengthens Ernexa’s Board as the Company advances ERNA-101 toward clinical development

CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced the appointment of Robert J. Spiegel, M.D., FACP, to its Board of Directors.

Dr. Spiegel is an accomplished physician, biopharmaceutical executive and drug developer

Form 8-K Ernexa Therapeutics Inc. For: Sep 16

Wed, 16 Sep 2026 17:31:00 -0400
si-local-file:///var/storage/secattach/20260916/27071258.html

Form 8-K Ernexa Therapeutics Inc. For: Sep 14

Wed, 16 Sep 2026 16:51:00 -0400
si-local-file:///var/storage/secattach/20260916/27070928.html